Expanding its CNS portfolio, Sumitomo Dainippon Pharma’s Sunovion Pharmaceuticals has agreed to acquire Canadian biotech Cynapsus Therapeutics for approximately US$624 M in cash. Cynapsus’ sole asset is APL-130277, a Phase III sublingual film formulation of apomorphine that is designed to treat the debilitating ‘OFF’ episodes associated with Parkinson’s disease. It offers a more convenient mode of administration and an improved side-effect profile compared to subcutaneously delivered apomorphine.